TSOPFPATEPT: The Selection of Pregnancy for Patients After Tubal Ectopic Pregnancy Treatment

Sponsor
Shanghai First Maternity and Infant Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05498558
Collaborator
Shanghai Seventh People's Hospital (Other), Shanghai Zhoupu Hospital (Other), Shanghai Pudong Hospital (Other)
400
1
12
33.4

Study Details

Study Description

Brief Summary

The incidence of re-ectopic pregnancy in patients with tubal ectopic pregnancy increases significantly, which may be related to the condition of the fallopian tubes, such as tubal inflammation, tubal obstruction and other high-risk factors that may lead to tubal ectopic pregnancy; it is also associated with the treatment of the previous tubal ectopic pregnancy. Compared with salpingectomy, the treatment of preserving the fallopian tubes increased the incidence of re-ectopic pregnancy while increasing the pregnancy rate of the patient. For tubal-preserving patients, the most common option currently used is to recommend that monitoring ovulation during each menstrual cycle if they choose to conceive naturally rather than IVF. If ovulation occures on the healthy side of the ovary, it may be considered to try to conceive; Otherwise, contraception is recommended. However, there are uncertainties about this option. Based on this, we intend to conduct a multicenter clinical trial to verify the effectiveness of the ovulation preparation regimen on the healthy side of ovary.

Condition or Disease Intervention/Treatment Phase
  • Other: No intervention.

Detailed Description

Tubal ectopic pregnancy is a disease that seriously affects women's physical and mental health and reproductive health, not only can there be some short-term complications such as rupture of tubal pregnancy and massive bleeding in the abdominal cavity, but also can lead to a decrease in female fertility, and the incidence of subsequent ectopic pregnancy has increased significantly. In recent years, with the development of diagnosis and treatment methods, the proportion of serious clinical events such as rupture of tubal pregnancy and massive hemorrhage in patients has decreased significantly. However, there is little research on the long-term damage of tubal pregnancy to women's fertility, especially how to avoid the occurrence of re-ectopic pregnancy, and there is no definitive and effective program.The incidence of re-ectopic pregnancy in patients with tubal ectopic pregnancy increases significantly, which may be related to the condition of the fallopian tubes, such as tubal inflammation, tubal obstruction and other high-risk factors that may lead to tubal ectopic pregnancy; it is also associated with the treatment of the previous tubal ectopic pregnancy. Compared with salpingectomy, the treatment of preserving the fallopian tubes increased the incidence of re-ectopic pregnancy while increasing the pregnancy rate of the patient.It is reported that the incidence of re-ectopic pregnancy in patients who choose salpingotomy is significantly higher than salpingectomy.Patients receiving conservative treatment and expectant treatment with methotrexate have a similar incidence of re-ectopic pregnancy as in patients receving salpingotomy.For tubal-preserving patients, the most common option currently used is to recommend that monitoring ovulation during each menstrual cycle if they choose to conceive naturally rather than IVF. If ovulation occures on the healthy side of the ovary, it may be considered to try to conceive; Otherwise, contraception is recommended. However, there are uncertainties about this option. Based on this, we intend to conduct a multicenter clinical trial to verify the effectiveness of the ovulation preparation program on the healthy side of ovary.We plan to randomly divide patients who meet the inclusion criteria into two groups:preparation for pregnancy in each ovulatory cycle and in healthy ovulatory cycle. Monitor the development of the patient's follicles each cycle, follow the patient to pregnancy, and analyze the patient's ovulation rate of healthy ovary, pregnancy rate, ectopic pregnancy rate and the time required from preparation to be pregnant, so as to determine whether the healthy side ovulation preparation program can improve the patient's normal pregnancy rate and reduce the ectopic pregnancy rate.

Study Design

Study Type:
Observational
Anticipated Enrollment :
400 participants
Observational Model:
Other
Time Perspective:
Prospective
Official Title:
The Selection of Pregnancy for Patients After Tubal Ectopic Pregnancy Treatment In Pudong New Area
Anticipated Study Start Date :
Jan 1, 2023
Anticipated Primary Completion Date :
Oct 30, 2023
Anticipated Study Completion Date :
Dec 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Ovulation occurs on the healthy side

In tubal-presering patient who received treatment of tubal ectopic pregnancy,only when ovulation occurs on the healthy side of ovary,it may be considered to try to conceive; otherwise, contraception is recommended.

Other: No intervention.
No intervention.

Ovulation occurs on the either side

In tubal-presering patient who received treatment of tubal ectopic pregnancy,ovulation occurs on the either side of ovary,it may be considered to try to conceive.

Other: No intervention.
No intervention.

Outcome Measures

Primary Outcome Measures

  1. Rate of tubal pregnancy within12 months in both groups of patients. [2023.10]

    Tubal ectopic pregnancy refers to the implantation of embryo in the fallopian tubes.

Secondary Outcome Measures

  1. Rates of pregnancy and miscarriage within 12 months in both groups of patients. [2023.10]

    Clinical pregnancy is defined as ultrasound suggesting a gestational sac, with or without fetal heartbeat; miscarriage is defined as ultrasound suggesting that the fetus is inanimate or that the fetus has miscarried spontaneously.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 41 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. After tubal pregnancy treatment (including expectant therapy, medication, salpingotomy), the blood hCG value returns to normal;

  2. The patient has fertility requirements;

  3. The age of the patient is between 18-41 years old;

  4. Regular menstruation;

  5. There is no abnormality in the husband's semen examination;

  6. No history of sex hormone drugs in the 3 months prior to the examination;

  7. No underlying diseases such as heart, liver, kidneys and brain;

  8. No history of tuberculosis;

  9. Normal blood routine examination (WBC≥ 4109/L, HB≥100g/L, PLT≥100109/L);

  10. Normal liver and kidney function tests;

  11. Normal thyroid function;

  12. The patient can withstand and receive follicle monitoring during pregnancy;

  13. Negative for pregnancy test before treatment.

Exclusion Criteria:
  1. Cervical pregnancy, cesarean scar pregnancy, cornual pregnancy, interstitial pregnancy;

  2. The age of the patient < 18 years or > 41 years;

  3. Irregular menstruation or abnormal results of sex hormone tests during follow-up;

  4. Abnormal results of the man's semen examination during the follow-up period;

  5. The patient has a tendency to bleed easily;

  6. History of myometriosis and endometriosis;

  7. Abnormal blood routine examination or liver and kidney function;

  8. History of cardiovascular diseases, including severe hypertension, severe arrhythmias, history of myocardial infarction;

  9. History of hepatitis B or C infection and patient has a detectable viral load;

  10. Patients with active tuberculosis;

  11. History of malignant tumors;

  12. Unable to regularly monitor the follicles during pregnancy;

  13. Unconditional long-term follow-up;

Contacts and Locations

Locations

Site City State Country Postal Code
1 Shanghai First Maternity and Infant Hospital Shanghai Shanghai China 200120

Sponsors and Collaborators

  • Shanghai First Maternity and Infant Hospital
  • Shanghai Seventh People's Hospital
  • Shanghai Zhoupu Hospital
  • Shanghai Pudong Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Shanghai First Maternity and Infant Hospital
ClinicalTrials.gov Identifier:
NCT05498558
Other Study ID Numbers:
  • ShanghaiFMIH2022-LSD
First Posted:
Aug 12, 2022
Last Update Posted:
Aug 12, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 12, 2022